Literature DB >> 16202544

EWS-ETS oncoproteins: the linchpins of Ewing tumors.

Ralf Janknecht1.   

Abstract

Ewing tumors, which comprise Ewing's sarcoma and peripheral primitive neuroectodermal tumors, are highly aggressive and mostly affect children and adolescents. Their molecular signature is a chromosomal translocation leading to the generation of EWS-ETS (or very rarely FUS-ETS) fusion proteins that are capable of transforming cells. These oncoproteins act as aberrant transcription factors due to the fusion of an ETS DNA binding domain to a highly potent EWS (or FUS) transactivation domain. Accordingly, many EWS-ETS target genes have been identified whose dysregulation could contribute to the development of tumor formation. Furthermore, EWS-ETS oncoproteins may impact on RNA splicing or affect other proteins through disturbing their ability to form functional complexes. The molecular knowledge gained so far from studying EWS-ETS oncoproteins has not only broadened our understanding of Ewing tumors but also improved the diagnosis of these highly undifferentiated tumors. In addition, several potential prognostic markers have been uncovered and novel therapies are suggested that may improve the still dismal survival rate of Ewing tumor patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16202544     DOI: 10.1016/j.gene.2005.08.007

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  67 in total

Review 1.  Targeted therapy in bone and soft tissue sarcoma in children and adolescents.

Authors:  Patrick A Thompson; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 2.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

Review 3.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

Review 4.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

Review 5.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

6.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

7.  ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.

Authors:  Sook Shin; Sangphil Oh; Seayoon An; Ralf Janknecht
Journal:  Oncol Rep       Date:  2012-10-16       Impact factor: 3.906

8.  EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations.

Authors:  Robert Beck; Michael J Monument; W Scott Watkins; Richard Smith; Kenneth M Boucher; Joshua D Schiffman; Lynn B Jorde; R Lor Randall; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2012-06

9.  GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.

Authors:  Jay Joo; Laura Christensen; Kegan Warner; Leith States; Hyung-Gyoo Kang; Kieuhoa Vo; Elizabeth R Lawlor; William A May
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

Review 10.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.